Real-world utility of ctDNA NGS to identify matched targeted therapy

Liquid biopsy for plasma circulating tumour DNA (ctDNA) next generation sequencing (NGS) is a rapidly evolving science. Plasma ctDNA assays are now commercially available, and are increasingly adopted in the community with a paucity of evidence-based guidance on timing and value of this test. Sabari et al. sought to determine the feasibility and utility of plasma ctDNA NGS to identify matched targeted therapy in a real-world clinical setting. At two sites, a total of 27 patients with metastatic adenocarcinoma of the lung and unknown driver mutation or unknown resistance mechanism were enrolled.